Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02899533 · ClinicalTrials.gov registry record
[18F]FES PET/CT in PAH
A clinical trial, sponsored by University of Pennsylvania.
- Terminated
- Registry status
- 5
- Enrollment target
NCT02899533: Clinical Trial study, sponsored by University of Pennsylvania.
NCT02899533 is a clinical trial that was terminated before completion, run by University of Pennsylvania. The registered enrollment target is 5 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02899533 was terminated before completion, sponsored by University of Pennsylvania.
- TERMINATED
- Registry status
- 5 participants
- Enrollment target
Study Summary
In this study positron emission tomography (PET/CT) imaging will be used to evaluate evaluation of estrogen receptor heterogeneity and functionality in Pulmonary Arterial Hypertension (PAH) using the investigational radiotracer \[18F\]fluoroestradiol (FES).
Primary Outcome
Patients will have a baseline FES PET/CT scan prior to the initiation of fulvestrant and a second FES PET/CT scan 9 weeks after the initiation of fulvestrant.
Interventions
- DRUG [18F] FES
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2016-07 |
| Est. Completion | 2021-04-06 |
Why NCT02899533 stopped before completion
NCT02899533 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 5 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which [18F] FES is the first listed.
NCT02899533 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02899533 about?
NCT02899533 is a clinical study titled "[18F]FES PET/CT in PAH". In this study positron emission tomography (PET/CT) imaging will be used to evaluate evaluation of estrogen receptor heterogeneity and functionality in Pulmonary Arterial Hypertension (PAH) using the investigational radiotracer \[18F\]fluoroestradiol (FES).
What is the current status of trial NCT02899533?
This trial is currently terminated. The enrollment target is 5 participants. The study started on 2016-07. Estimated completion is 2021-04-06.
What interventions are being tested in trial NCT02899533?
The interventions under investigation include: [18F] FES (DRUG).
Who is sponsoring clinical trial NCT02899533?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia